Summary Nine human small-cell lung cancer cell lines were treated with transforming growth factor , (TGF-,B,). Seven of the cell lines expressed receptors for transforming growth factor P (TGF-p-r) in different combinations between the three human subtypes I, II and III, and two were receptor negative. Growth suppression was induced by TGF-P, exclusively The transforming growth factor betas (TGF-P) constitute a family of polypeptides which have been shown to be multifunctional regulators of basic cellular functions such as proliferation, differentiation, cell adhesion and interactions with extracellular matrix (Massague, 1990; Roberts & Sporn, 1990; Moses, 1992) .
The transforming growth factor betas (TGF-P) constitute a family of polypeptides which have been shown to be multifunctional regulators of basic cellular functions such as proliferation, differentiation, cell adhesion and interactions with extracellular matrix (Massague, 1990; Roberts & Sporn, 1990; Moses, 1992) .
Five different isoforms of TGF-P have been described, of which a wide range of human cells express TGF-p1, TGF-P2, and TGF-P3 (Derynck et al., 1985 (Derynck et al., , 1988 de Martin et al., 1987; ten Dijke et al., 1988) . TGF-P binds to cell membranebound receptors. Three types (TGF-,-rI, -II and -III) are expressed by a variety of human cells, both normal and malignant (for review see Massague et al., 1992) . TGF-P-rI and -II are glycoproteins and their recent cloning revealed an intracellular serine/threonine kinase domain (Lin et al., 1992; Ebner et al., 1993) , which is believed to play a role in the initial signal transduction. It has been proposed that TGF-P-rI and -II signal through formation of a heterodimeric complex . TGF-P-rIII, which is a proteoglycan (betaglycan), has also been cloned (LopezCasillas et al., 1991; Wang et al., 1991) and apparently has no direct role in signal transduction, but may act as a capacitor for the signalling receptors. TGF-P1 exerts a growth-suppressive effect on a wide range of normal (Massague, 1990 ) and malignant human cells, including ovarian carcinoma (Berchuck et al., 1992) , mammary carcinoma (Knabbe et al., 1987; Arteaga et al., 1988) , endometrial carcinoma (Boyd & Kaufman, 1990) , colon carcinoma (Wu et al., 1992) , prostate carcinoma (Wilding et al., 1989) and gastric carcinoma (Yanagihara & Tsumuraya, 1992) . Only one small-cell lung cancer (SCLC) cell line has previously been reported to be growth inhibited by TGF-P (Lagadec et al., 1991) .
The intracellular signalling pathway of TGF-P is still obscure. The protein product of the retinoblastoma gene (pRb) has been proposed to be involved in the pathway mediating TGF-P1 growth inhibition in vitro in mink lung cells (Laiho et al., 1990a) and in human keratinocytes (Pietenpol et al., 1990) . In contrast, it has been shown that in a mammary carcinoma cell line pRb is not an obligatory component of this pathway (Ong et al., 1991) . Retinoblastoma protein has properties of a cell cycle regulatory factor in that its phosphorylation state varies through the cell cycle, with a highly phosphorylated form predominating in S and G2/M, and an underphosphorylated form predominating in GI. Aberrant, non-functional, protein products of mutated Rb genes have been characterised and shown to have lost the ability to become hyperphosphorylated and to associate with nuclear structures (Szekely et al., 1991; Templeton et al., 1991) .
Recently, the expressions of TGF-P-r types I, II and III were examined by chemical cross-linking to TGF-P3 in a panel of 21 human small-cell lung cancer cell lines (SCLCs) in our laboratory (Damstrup et al., 1993) . Different combinations of the three receptor types were expressed in seven cell lines. Using the Northern blotting technique the expression of TGF-pl, TGF-P2 and TGF-P3 mRNAs was examined and coexpression of TGF-p-r and TGF-P mRNA was found in six cell lines. Another six cell lines were found only to express TGF-P mRNA.
The expression of Rb mRNA and pRb in the panel of SCLC cell lines has been reported previously (Rygaard et al., 1990) . Using Western blotting, it was shown that in five of the 17 cell lines phosphorylated pRb was expressed, indicating expression of a functional retinoblastoma protein.
In this study the functionality of the TGF,B receptors in SCLC and the possible involvement of pRb in mediating the effect of TGF-P, were investigated. We characterised the effect on the growth of the seven TGF-,-r-positive and of two TGF-p-r negative cell lines of continuous treatment with exogenous TGF-pl, and (Pettengill et al., 1980; Sorenson et al., 1984) were cultured in Waymouth medium (Gibco, Paisley, UK). Four cell lines established at Groningen Lung Cancer Center (Groningen, The Netherlands) (GLC 3, GLC 14, GLC 16, GLC 19) (De Leij et al., 1985; Berendsen et al., 1988) were cultured in RPMI-1640 (Gibco), and two cell lines established in our laboratory (CPH 54A, CPH 54B) (Engelholm et al., 1986) were grown in EMEM (Eagle's minimum essential medium) (Gibco). AKR-2B, a mouse fibroblast cell line that has previously been reported to be TGF-p-r positive, (Tucker et al., 1984) , was cultured in EMEM supplemented with 10% FCS, and used in the displacement assay described below. AKR-2B was kindly provided by Professor H.L. Moses (Vanderbilt University, TN, USA). The cells were passaged twice a week. Cells growing as monolayer cultures (CPH 54A, CPH 54B, DMS 53, DMS 114, DMS 273) were passaged with trypsin. Cells growing as floating aggregates (GLC 3, GLC 14, GLC 16, GLC 19) were allowed to sediment before replacing the medium. All cell lines were routinely checked for, and found to be free of, mycoplasma infection.
Growth factor
Porcine TGF-P, was purchased from British Biotechnology (Oxford, UK) and/or was a gift from Bristol-Myers Squibb (Pharmaceutical Research Institute, Seattle, WA, USA). One microgram of dried TGF-P, was reconstituted in 0.5 ml of 4 mM hydrochloric acid containing 2 mg ml-l BSA, and stored at + 4°C. Fresh TGF-1, stock solution was tested for the ability to displace '25I-labelled TGF-3, in AKR-2B cells using a radioreceptor assay as described elsewhere (Damstrup et al., 1993) . For growth assays, solutions of TGF-P, in culture medium containing 10% inactivated (56°C, 30 min) FCS without antibiotics were made immediately before each experiment.
Growth assay
Exponentially growing cells were harvested as described above, resuspended in PBS and centrifuged at 275 g for 5 min. A single-cell suspension was obtained by mechanical disaggregation. Cells were counted in a haemocytometer and viability was evaluated by trypan blue exclusion. Viable cells were seeded in 35 mm six-well tissue dishes (Costar, Cambridge, USA), 5-20 x I04 in 3 ml of culture medium per well. Cells growing as monolayer cultures were allowed to attach for 24 h. Culture medium was removed and medium containing TGF-3, was added (designated day 0). Loosely adhering monolayer cultures were supplemented with TGF-P3,-containing medium (day 0). Cells growing as floating aggregates were seeded directly in TGF-p1-containing medium (day 0). The cells were treated with TGF-P1 in concentrations corresponding to absence of ligand (O pM) , the average KD for TGF-PI binding to the TGF-,B receptors (20 pM) (Damstrup et al., 1993) , saturation of the receptors (100 pM) and excess of ligand (250 pM). Fresh medium containing TGF-P, was added every 48 h. Growth data were based on repeated (approximately 48 h) harvest and assaying of triplicate wells of each of the four TGF-PI concentrations. Samples of cells growing strictly as monolayer cultures (CPH 54A and CPH 54B) were assayed for total protein (see below). All other cells were assayed for DNA content (see below). Each experiment was extended until the plateau phase of the growth curve for the control (TGF-P, 0 pM) was reached. All experiments were reproduced at least twice.
Protein determination Culture medium was removed from the six-well dishes and the cells were washed twice with cold phosphate-buffered saline (PBS). The cells were solubilised in solubilisation buffer [128 mM sodium chloride, 0.25 mM EDTA, 0.5 mM Tris pH 7.5 and 1% (v/v) Triton X-100]. Protein concentration was determined using the BCA protein kit (Pierce Europe, Oud Beijerland, The Netherlands) (Smith et al., 1985) .
DNA determination Medium containing cells was sampled and the plates were further harvested by trypsinisation. The cells from each well were pelleted by centrifugation (1,200 g, 10 min) and homogenised by ultrasonication in 1.0 -2.0 ml of fluorimetry buffer (2.0 M sodium chloride, 10 mM Tris, 5 mM EDTA, pH 7.4). The DNA content of 20 LIl of homogenate plus 2.0 ml of fluorimetry buffer containing 0.1 tg ml-' bisbenzimide (Hoechst dye no. 33258) was determined by fluorimetry (Labarca & Paigen, 1980) 
Statistics
The total content of protein or DNA was expressed relative to the content at day 0 to obtain a relative increment in cell number. Growth curves were constructed by plotting the relative increment as a function of time. Each growth curve was parameterised using quadratic regression on the logtransformed increments. The estimated coefficients of treated and control cells were compared using multivariant statistics and the significance level expressed. as a P-value. Values below 0.01 were regarded as significant.
Results

Growth suppression
The results of the TGF-P, treatment and the immunocytochemical investigation of pRb localisation are summarised in Table I suppressed by TGF-P, (Table I) . These results showed that only in the cell lines expressing TGF-p-r type II did treatment with TGF-01 result in growth suppression, and this suggested that in SCLC TGF-p-r type II mediated the growth-suppressive effect of TGF-p,. The maximum growth inhibition was approximately the same in all the responding cell lines, and as expected the inhibitory effect emerged later in the slower growing cell lines. This indicated that in SCLC no obligatory coexpression between TGF-p-rII and type I or III was required for mediation of TGF-P1 growth suppression. However, this panel of cell lines did not include cells expressing TGF-p-rII or TGF-p-rI alone, or TGF-p-rI coexpressed with TGF-p-rIII. Therefore, it could not be established whether these receptor profiles were capable of mediating a response to TGF-p1. An apparent growth inhibition of the TGF-P-r-negative cell line DMS 53 did occur very late in the experiment with high TGF-P, concentrations. A possible explanation could be that this cell line expressed TGF-p-r in a concentration below the detection limit with chemical cross-linking and radioreceptor assays.
A few reports have elucidated the issue of functional diversity and/or correlation among the TGF-P receptors, and it has become apparent that different mechanisms operate in different model systems. In a recent study, Geiser et al.
(1992) used a human bladder carcinoma and a human colon adenocarcinoma, which were both resistant to the growthinhibitory action of TGF-, but responded to TGF-P by producing increased levels of mRNA for extracellular matrix proteins. When fused, a non-tumorigenic hybrid was produced, in which the effect of TGF-f on growth was restored, accompanied by a marked increase in TGF-p-rII expression.
In another report, transfection of hepatoma cells with the type II receptor cDNA resulted in restoration of growth suppression by TGF-P, (Inagaki et al., 1993) . Our present results support these findings, and emphasise the role of TGF-p-r type II in mediating growth inhibition, because the SCLC cell line DMS 273 represents the first reported case of growth suppression by TGF-P1 mediated by the type II receptor without coexpression of the type I receptor (Table I and Figure 1) .
A model for functional interrelation between TGF-p-rI and -II was recently presented , based on studies of mutated mink lung epithelial cells (Boyd & Massague, 1989; Laiho et al., 1990a Laiho et al., ,b, 1991 Wrana et al., 1992) .
According to this model TGF-p-rI and TGF-p-rII form a heterodimeric complex for signalling of the various effects of TGF-P, including suppression of growth. As described above, our present results concerning the SCLC cell line DMS 273
do not agree with this heteromeric TGF-P receptor model.
However, the possibility exists that DMS 273 expressed TGF-P-rI at a concentration below the detection limit of the chemical cross-linking assay (Damstrup et al., 1993) .
TGF-P is supposed to be a central regulator in the normal coordination of growth and differentiation, through autocrine and paracrine mechanisms. A perturbation of the balance between negative and positive growth regulators could lead to an increased proliferative potential, and contribute to the neoplastic phenotype . We previously reported coexpression of TGF-P and TGF-p-r in six of 21 examined SCLC cell lines (Damstrup et al., 1993 by TGF-pJ. It is possible that in these three cell lines, together with the cell lines that expressed TGF-P mRNA but no receptors (Damstrup et al., 1993) , loss of autocrine growth inhibition by TGF-P contributes to the malignant phenotype. It can, however, be concluded from the present result that this putative mechanism in tumour progression is not a general phenomenon in SCLC. Induction of altered morphology by TGF-1 was previously described (Fanger et al., 1986; Koyasu et al., 1988; Boyd & Kaufman, 1990) , and could be expected from its effect on the expression of a wide variety of structural proteins (reviewed in Massague, 1990 (Table  I) , but given the knowledge that TGF-1-rIII apparently has no direct role in signal transduction, and the finding that the growth suppression was equal in all responsive cell lines, it seemed unlikely that the coexpression of TGF-p-rIII in CPH 54A and CPH 54B, alone should determine this difference.
We also examined the possible involvement of the retinoblastoma protein in mediating the growth inhibition of TGF-P1. Previously the expression of Rb mRNA and pRb in our panel of SCLC cell lines was characterised (Rygaard et al., 1990) . Western blotting showed expression of pRb in five of the nine cell lines examined in this study (Table I ), but in DMS 273 the protein was not phosphorylated. Given the fact that pRb was isolated from exponentially growing cells, and thus representative of all cell cycle phases, the dephosphorylation of the protein in DMS 273 indicated that it was non-functional (Templeton et al., 1991) . Using immunocytochemistry, we further investigated the functional state of pRb by evaluating the amount of nuclear localisation of the protein (Table I) . Only CPH 54A, CPH 54B, DMS 114 and DMS 53 showed predominantly nuclear staining (Figure 3) . Aberrant, non-functional, protein products of mutated Rb genes have been characterised and shown to have lost the ability to become hyperphosphorylated and to associate with nuclear structures (Szekely et al., 1991; Templeton et al., 1991) . Our present results showed that an SCLC cell line expressing non-functional pRb (DMS 273) or cell lines wihout pRb expression (GLC 16 and GLC 19) can be growth inhibited by TGF-p,. These findings indicated that in these cell lines there was no correlation between responsiveness to the growth-suppressive effect of TGF-P, and expression of functional pRb, and strongly suggest that in SCLC pRb is not an obligatory component in the TGF-P, growth suppression pathway. This conclusion is in agreement with the finding that TGF-P could inhibit the growth of mammary carcinoma cell lines in the complete absence of pRb expression (Ong et al., 1991) . In contrast, evidence has been provided that pRb plays a part in the TGF-P signalling pathway in mink lung epithelial cells (Laiho et al., 1990b) and in human skin keratinocytes (Pietenpol et al., 1990) . It was found that TGF-P, inhibition of proliferation involves suppression of c-myc expression and is abrogated by pRb-binding viral transforming proteins (Pietenpol et al., 1990) . The c-myc promoter region mediating this effect, called the TGF-P control element, is also required for pRb suppression of c-myc (Pietenpol et al., 1991) . The role of pRb in the TGF-P signalling pathway is apparently not definitive, and TGF-P signal transduction therefore probably functions through different mechanisms in different cell types.
